Bristol Myers Squibb (CELG-RI) Intangibles (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Intangibles for 18 consecutive years, with $17.4 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Intangibles fell 18.67% year-over-year to $17.4 billion; the TTM figure through Jun 2026 stood at $17.4 billion (down 18.67% YoY), while the FY2025 annual figure was $19.1 billion, down 18.04% from the prior year.
• Intangibles slipped to $17.4 billion in Q2 2026 per CELG-RI's latest filing, from $18.2 billion in the prior quarter.
• Across five years, Intangibles topped out at $40.1 billion in Q1 2022 and bottomed at $17.4 billion in Q2 2026.
• Historically, Intangibles has averaged $28.0 billion across 5 years, with a median of $28.0 billion in 2023.
• Annual changes were most pronounced in 2024 — Intangibles retreated 2.41% — and 2025, when it plunged 31.36%.
• Bristol Myers Squibb's Intangibles stood at $35.9 billion in 2022, then decreased by 24.5% to $27.1 billion in 2023, then declined by 13.91% to $23.3 billion in 2024, then declined by 18.04% to $19.1 billion in 2025, then declined by 8.98% to $17.4 billion in 2026.
• Business Quant data shows CELG-RI's Intangibles at $17.4 billion in Q2 2026, $18.2 billion in Q1 2026, and $19.1 billion in Q4 2025.